KR101753063B1 - The manufacturing method of the Astragalus membranaceus having increased antioxidant substances - Google Patents
The manufacturing method of the Astragalus membranaceus having increased antioxidant substances Download PDFInfo
- Publication number
- KR101753063B1 KR101753063B1 KR1020150152303A KR20150152303A KR101753063B1 KR 101753063 B1 KR101753063 B1 KR 101753063B1 KR 1020150152303 A KR1020150152303 A KR 1020150152303A KR 20150152303 A KR20150152303 A KR 20150152303A KR 101753063 B1 KR101753063 B1 KR 101753063B1
- Authority
- KR
- South Korea
- Prior art keywords
- present
- antioxidant
- hwanggi
- extract
- increased
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/16—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating loose unpacked materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/115—Cereal fibre products, e.g. bran, husk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to an antioxidant composition comprising an antioxidant component ( Astragalus The present invention relates to a method for producing membranaceus , and more particularly, to a method for preparing a fermented starch, which comprises fermenting Phellinus linteus strain after sterilization with rice bran mixture and distilled water, By confirming that the contents of calycosin and formononetin as functional ingredients are increased, the process for preparing hulls of the present invention can be effectively utilized as a method for producing hulls with increased antioxidant components.
Description
The present invention relates to an antioxidant composition comprising an antioxidant component ( Astragalus membranaceus . < / RTI >
Astragalus membranaceus ) is a perennial herb with roots of dicotyledonous roots, which grows in the rocks of the mountain. It is mainly distributed in Korea, Japan, Manchuria, Northeastern China, and Eastern Siberia. Hwanggi is often cultivated as an herb, and it is collected in the autumn in an oriental herb, and it is called "Hwanggi" of herbal medicines. It is prescribed for the weakness of the body, fatigue boredom, blood depression, defecation, stomachache, internal sewage, cold sweat, peripheral nerve. Although the above-mentioned medicinal herb has been used as a part of herbal medicinal materials, the most commonly used form is used for boiling herbs together with chickens when she takes her summer sundown samgyetang.
Hwanggi is mainly used in herbal medicine rather than food. It is used for the purpose of jisan, diuretic, tincture and blood pressure lowering. In pharmacological experiments, diuretic action, tonic action, hypotensive action, hypoglycemic action, immune enhancement action, anti- And viral action, and physiologically active substances present in the yellow period include formononetin, triterpenoide glycoside, and β-sitosterol, which are one of isoflavone glycosides. β-sitosterol) and saponins as astragalosides and sugars as main components.
The present invention relates to a method for the treatment of osteoporosis comprising an extract of Huangji as an active ingredient, a method of producing Korean patent No. 10-0843276, 10-0195884, and a composition for preventing ischemic neuronal damage comprising brain stem extract of Korean Patent No. 10-0526404.
Studies on the technology using the hwanggi as a main component or the physiologically active ingredient of the hwanggi have been carried out. However, studies on improving the quality of the hwanggi and enhancing the functional ingredients are still insufficient. Accordingly, the inventors of the present invention have found that when a functional ingredient of hwanggi is intensively studied, the functional ingredient is remarkably increased when the microorganism and distilled water are mixed and sterilized in the hwanggi period and then the benthic microbial strain is inoculated and fermented, Thus completing the present invention.
An object of the present invention the Astragalus antioxidants increase (Astragalus membranaceus of the present invention.
In order to achieve the above object,
1) Astragalus pulverizing membranaceus in the form of sawdust to produce an emulsion;
2) sterilizing the mixture of the crushed hull, rice bran and distilled water of step 1); And
3) To the sterilized product of step 2) above was added Phellinus The present invention also provides a method for producing an egg white having increased antioxidant components, comprising the step of inoculating a strain of Linteus , followed by culturing and fermenting the strain.
In addition, the present invention provides an increased number of antioxidant components produced by the method of the present invention.
In addition, the present invention provides an extract of Hwanggi extract obtained by extracting the hwanggi of the present invention with water, alcohol or a mixture thereof.
In addition, the present invention provides a composition comprising the hull of the present invention or the hull of the present invention.
The present invention relates to an antioxidant composition comprising an antioxidant component ( Astragalus Specifically, the present invention relates to a method for producing membranaceus which comprises fermenting Phellinus linteus strain after sterilization by mixing rice bran and distilled water, and producing a fermented soybean which has high reducing sugar and free sugar content, The content of calycosin and formononetin of the present invention is increased. Thus, the present invention can be advantageously used as a method for preparing an antioxidant component having an increased antioxidant component.
Figure 1 shows that the antioxidant component increased in the antioxidant component ( Astragalus membranaceus ) according to the present invention.
Hereinafter, the present invention will be described in detail.
According to the present invention,
1) Astragalus pulverizing membranaceus in the form of sawdust to produce an emulsion;
2) sterilizing the mixture of the crushed hull, rice bran and distilled water of step 1); And
3) Inoculating a Staphylococcus aureus strain into the sterilized product of step 2), followed by culturing and fermenting the same, wherein the antioxidant component is increased.
It is preferable that the sulfur and the bare steel in the step 2) are mixed at a ratio of 4: 1.
The sterilization in step 2) is preferably sterilized at a temperature of 100 to 140 ° C for 30 to 60 minutes, more preferably at a temperature of 110 to 130 ° C for 35 to 55 minutes, more preferably at a temperature of 120 to 122 ° C Lt; RTI ID = 0.0 > 40-42 < / RTI >
In step 3), the porcine bacillus is Phellinus linteus), horseshoe Mushroom (Fomes fomentarius), Ganoderma lucidum (Canoderma lucidum ), large mushroom ( Pleurotus eryngii , Flammulina velutipes , Lentinus edodes ) and mushroom No. 7 ( Pleurotus ostreatus Gonji - 7ho ) strains.
The fermentation of step 3) is preferably carried out at a temperature of 20 ° C to 30 ° C for 20 to 40 days, more preferably at a temperature of 22 ° C to 29 ° C for 25 to 35 days, It is most preferred to incubate for 30 to 32 days at temperature.
In a specific example of the present invention, the inventors of the present invention found that when the rice hull prepared by fermenting broccoli strain inoculated with rice bran and distilled water by mixing with Hwanggi was high in reducing sugar and free sugar content (see Tables 1 to 2) Calycosin and formononetin contents were increased (see Table 3). Thus, the present invention provides a method for preparing the crude oil of the present invention, .
In addition, the present invention provides an increased number of antioxidant components produced by the method of the present invention.
The erythrocyte has a high reducing sugar and free sugar content, and is characterized in that the content of calycosin and formononetin, which are functional ingredients of the erythrocyte, is increased.
According to the method for producing antioxidants of the present invention, the reducing sugar and the free sugar content of the fermented yeast prepared by fermenting the microorganism strain after inoculating the raw rice bran with distilled water and sterilizing the fermented rice bran were increased (see Tables 1 to 2 Calicosin and formononetin, which are the functional ingredients of hwanggi, are increased (see Table 3), and the antioxidant component produced by the hwanggi manufacturing method of the present invention is increased, And can be usefully used as food and food materials.
In addition, the present invention provides an extract of Hwanggi extract obtained by extracting the hwanggi of the present invention with water, alcohol or a mixture thereof.
The extract may be extracted using water, alcohol, or a mixture thereof. The extraction method is preferably, but not limited to, shaking extraction, Soxhlet extraction, or reflux extraction.
In addition, the present invention provides a composition comprising the hull of the present invention or the hull of the present invention.
Preferably, the composition is a medicament, a quasi-drug, a health functional food, or a cosmetic.
The antioxidant component of the present invention exhibited an increase in the reducing sugar and free sugar content (see Table 1 to Table 2), and the functional components of erythrocyte, calycosin and formononetin, (See Table 3), and the antioxidant component produced by the present invention of the present invention can be effectively used as a composition of medicines, quasi-drugs, health functional foods and cosmetics.
The composition of the present invention may further comprise a pharmaceutically acceptable carrier. The term " pharmaceutically acceptable "as used herein means that the composition is free of toxicity to cells or humans exposed to the composition. Compositions comprising a pharmaceutically acceptable carrier can be of various oral or parenteral formulations. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. The carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, But may be at least one selected from the group consisting of polyvinylpyrrolidone, physiological saline, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol and liquid paraffin, But are not limited to, ordinary carriers, excipients or diluents. The components can be added independently or in combination.
Solid formulations for oral administration may include tablet pills, powders, granules, capsules and the like, which may contain one or more excipients, such as starch, calcium carbonate, sucrose or lactose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
The pharmaceutical composition of the present invention may also be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, Or a pharmaceutically acceptable salt thereof.
The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. There is no particular restriction on the dosage, and it may vary depending on the body's absorption, body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of disease and the like. The pharmaceutical composition of the present invention is prepared in consideration of an effective dose range, and the unit dosage formulations thus formulated are classified according to the judgment of the expert who monitors or observes the administration of the drug, if necessary, Or may be administered several times at a predetermined time interval. Preferably, the composition of the present invention may be administered at a dose of 0.5 to 5000 mg / kg, preferably 50 to 500 mg / kg, more preferably 50 mg / kg, based on the amount of the hwanggi extract, The above administration may be carried out once a day or several times.
The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate may be selected from the range of 0.01 to 0.04 part by weight, specifically about 0.02 to 0.03 part by weight per 100 parts by weight of the health functional food of the present invention.
In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, A carbonating agent used in a carbonated beverage, and the like. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
The cosmetic of the present invention can be produced in the form of a general emulsified formulation and a solubilized formulation. Cosmetics of emulsified form include nutrition lotion, cream, essence, etc., and cosmetics of solubilized form have softening longevity. In addition to the cosmetic compositions of the present invention, they may be formulated as adjuvants which can be applied topically or systemically, which are conventionally used in the field of dermatology by containing dermatologically acceptable media or bases. Suitable cosmetic formulations include, for example, solutions, gels, solid or kneaded anhydrous products, emulsions obtained by dispersing the oil phase in water, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) In the form of a dispersing agent, in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a conical stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant.
In addition, the cosmetic of the present invention may further contain a fatty substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, , A perfume, a surfactant, water, an ionic or nonionic emulsifier, a filler, a sequestering and chelating agent, a preservative, a vitamin, a barrier, a wetting agent, a essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent, Or any other ingredient conventionally used in cosmetics, or adjuvants commonly used in the cosmetics or dermatology fields. And, the above ingredients can be introduced in amounts commonly used in the field of dermatology.
Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.
< Example 1> Production of Porcine Culture of Carriers
For the production of porcine bran cultured hwanggi, the hwanggi was pulverized into sawdust form and then mycelial body was inoculated and cultured.
Specifically, the strains used in the present invention were obtained from the National Institute of Horticultural Science, Phellinus linteus), horseshoe Mushroom (Fomes fomentarius), Ganoderma lucidum (Canoderma lucidum), a big oyster mushroom (Pleurotus eryngii , Flammulina velutipes , Lentinus edodes ) and the mushrooms of Gongji 7 ( Pleurotus ostreatus Gonji - 7ho ) was used for the cultivation of Astragalus membranaceus were purchased from Hanbangchon, Seoul, Korea for 3 years.
First, 5 kg of Hwanggi was pulverized into sawdust, 1.25 kg of rice bran and brown rice were added at a ratio of 4: 1, and mixed with distilled water. Then, 300 g of each of the rice bran and rice bran was fed into a sawdust broth culture bottle, Scientific, Co., Ltd., Korea) for 40 minutes at 120 ° C. Then, each of the above-mentioned seven strain plates was inoculated into each culture bottle and fermented by incubating in an incubator (VS-1203PFHLN, Vision Scientific, Co., Ltd., Korea) at 25 ° C for 30 days. After incubation for 24 hours in a deep freezer (Ilsin BioBase co., Ltd., Korea), Hwanggi was cultivated in a freeze dryer (lsin BioBase co. The lyophilized product was ground and used as a sample.
< Example 2> Production of Porcine Hwanggi Extract from Porcine Culture
The bacterial cells cultured in Example 1 were extracted with water and 80% ethanol.
Specifically, water and 80% ethanol extracts were prepared using the lyophilized cultured egg yolk cultured in Example 1, respectively. For the 80% ethanol extract, 100 ml of 80% ethanol solution was added to 5 g of the lyophilized culture, and the mixture was centrifuged twice with an Ultrasound Gator (Power Sonic 420, 50/60 Hz, 700 W, Hwashin Co., After sonication by sonication and extraction, After filtration using 2 filter paper, the filtrate was adjusted to 200 mL and concentrated under reduced pressure at 50 ° C or lower using a rotary vacuum evaporator (BUCHI, USA). The concentrate was lyophilized and powdered. The preparation of hot water extract is as follows. After mixing 100 ml of boiled distilled water in 5 g of each culture, the mixture was repeatedly extracted twice for 1 hour with an Ultrasound Gator (Power Sonic 420, 50/60 HZ, 700 W, Hwashin Co., Korea). 2 filter paper, and the filtrate was concentrated by vacuum rotary evaporator (BUCHI, USA) at 50 ° C or lower and freeze-dried to prepare powder.
< Experimental Example 1> Identification of reducing sugar content in cultured porcine bacillus
The reducing sugar content of the 80% ethanol extract and the hot-water extract of the cultured eggplant-like cells produced in Example 2 was measured.
Specifically, 1 μl of a DNS sample was added to 1 ml of each of an 80% ethanol extract of Hwanggi and a 10% hot water extract of Hwanggi according to dinitrosalicylic acid (DNS) method, boiled for 15 minutes, cooled, and 3 ml of distilled water was added thereto. Absorbance was measured at a wavelength of 546 nm using a spectrophotometer (UV-visible spectrophotometer). At this time, the amount of sugar was calculated by converting glucose from the standard curve using glucose as a reference material.
As a result, as shown in Table 1, the amount of reducing sugar of F. velutipes was 391.74 ㎎ / 100 g, which was about twice that of non-inoculated, and the culture of P. linteus Hwang and Pleurotus mushroom mycelium (P. eryngii) exhibited a high content compared to non-inoculated culture Astragalus membranaceus Astragalus also not inoculated with the bacteria in each 346.73 ㎎ / 100 g, 289.97 ㎎ / 100 g ( Table 1). It is thought that the activity of bacterial enzymes was increased during the incubation period due to the action of α-amylase produced by bacillus thuringiensis.
The ANOVA was performed using SAS 9.2 (SAS Inc., Cary, NC, USA) and the results were analyzed by Ducan's multiple range test The results are as follows: a> b> c> d as the significant difference is significant.
< Experimental Example 2> Confirmation of free sugar content of Hwanggi extract
The free sugar content of the cultured egg yolk sac produced in Example 2 was confirmed.
Specifically, free sugar analysis was performed using HPLC (Waters 2695, waters Co., Miliford, MA, USA). The cell extract was diluted with 0.45 ㎛ PVDF membrane filter to obtain test solution. Prevail carbohydrate ES (5 ㎛, 4.6 × 250 ㎜) was used as the column and the column was mobile phase ) Was prepared by using an acetonitrile: water mixture (70:30, v / v), a flow rate of 1.0 ml / min and an ELSD Sigmal detector (Waters 2424, Waters Co., Miliford, MA, USA) Respectively.
As a result, as shown in Table 2, the content of fructose and sucrose in the 80% ethanol extract of basidiomycetes increased by about 1.2 to 2 times as compared with the control without inoculum. Among them, Fructose increased to 2154.61 ㎎ / 100 g in the cultivars of P. eryngii , and sucrose increased to 8929.60 ㎎ / 100 g in L. edodes cultivars . In the hydrothermal extracts of fungi, fructose was increased to 1528.03 ㎎ / 100 g in the culture broth of P. eryngii , and glucose, which was not detected in the control group, In the mycelium ( P. linteus ), 1547.51 g / 100 g was detected. It is decomposed into reducing sugars such as glucose by the decomposing enzyme of mycelium and used as a substrate for fermentation. The results are different because of the total amount and composition ratio of free sugars depending on the kinds of extraction solvent and basidiomycete.
(Fructose)
(Glucose)
(Sucrose)
(Fructose)
(Glucose)
(Sucrose)
The ANOVA was performed using SAS 9.2 (SAS Inc., Cary, NC, USA) and the results were analyzed by Ducan's multiple range test The results are as follows: a> b> c> d as the significant difference is significant.
< Experimental Example 3> Functional components analysis of Hwanggi extract
The functional components of the egg yolk extract cultured in Example 2 were analyzed.
Specifically, the contents of 80% ethanol and hot-water extract components of Baekjak culture were analyzed by HPLC (Waters 2695, Waters Co., Miliford, MA, USA). Each extract was filtered through a 0.45 μm PVDF membrane filter, and the test solution was analyzed. The mobile phase was prepared by using solvent A water: thrifluoro-acetic acid (99.5: 0.5, v / v) and solvent B Acetonitrile. The column was YMC-Pack Pro C18 (5 μm, 4.6 × 250 mm) , And the flow rate and column temperature were detected at 0.8 ml / min and 30 ° C respectively using a photodiode array detector (Waters 2699, Waters Co., Miliford, MA, USA) . Calycosin and formononetin were purchased from Sigma-Aldrich Co., and the three peak-area averages were taken from the HPLC and the correlation between the amount of the reference material and the peak area was determined Calibration curves were generated and calculated.
As a result, as shown in Table 3, the content of calycosin and formononetin, which are the major components of the hwanggi period and the major active ingredients, were 80% ethanol extract, which was cultured with P. linteus The extracts of P. linteus cultivated in the mushroom ( P. linteus ) showed a growth of 2 ~ 3.5 times higher than that of control group, which was not inoculated with bacillus subtilis . , And the content increased to 827.66 mg / g of calicosin and 221.28 mg / g of formononetin. This suggests that glycosyltransferase components in the hwanggi period can be converted into non - glycosylated forms of kalicosin and formononetin due to the enzymatic degradation of the strain, thereby increasing the absorption rate and bioavailability.
(Calycin)
(Formononetin)
(Calycin)
(Formononetin)
The ANOVA was performed using SAS 9.2 (SAS Inc., Cary, NC, USA) and the results were analyzed by Ducan's multiple range test The results are as follows: a> b> c> d as the significant difference is significant.
Claims (10)
2) sterilizing the mixture of the crushed hull, rice bran and distilled water of step 1); And
3) To the sterilized product of step 2) above was added Phellinus linteus strain, and then fermenting the strain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150152303A KR101753063B1 (en) | 2015-10-30 | 2015-10-30 | The manufacturing method of the Astragalus membranaceus having increased antioxidant substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150152303A KR101753063B1 (en) | 2015-10-30 | 2015-10-30 | The manufacturing method of the Astragalus membranaceus having increased antioxidant substances |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170050572A KR20170050572A (en) | 2017-05-11 |
| KR101753063B1 true KR101753063B1 (en) | 2017-07-06 |
Family
ID=58741510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150152303A KR101753063B1 (en) | 2015-10-30 | 2015-10-30 | The manufacturing method of the Astragalus membranaceus having increased antioxidant substances |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101753063B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210031285A (en) | 2019-09-11 | 2021-03-19 | 선문대학교 산학협력단 | Formononetin 7-O-phosphate and Composition for Anti-inflammatory Comprising the Same |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102175244B1 (en) * | 2018-11-06 | 2020-11-06 | 대한민국 | antioxidant composition comprising Astragalus membranaceus and method of manufacturing the same |
| KR102304146B1 (en) * | 2018-12-14 | 2021-09-24 | 대한민국 | Composition for skin whitening and composition for ultraviolet-proof comprising the extract of fermented Astragalus membranaceus Bunge |
| KR102266936B1 (en) * | 2018-12-14 | 2021-06-21 | 대한민국 | Pharmaceutical composition for treating or preventing inflammatory diseases comprising the extract of fermented Astragalus membranaceus Bunge |
| KR102262551B1 (en) * | 2020-09-29 | 2021-06-09 | 부경 주식회사 | Manufacturing Method of Soup using Chicken Breast and Soup Composition using Chicken Breast |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101148513B1 (en) * | 2011-07-16 | 2012-05-21 | 최재홍 | Method for preparing producing an enrichment composition of ergothioneine from gastrodiae elata |
-
2015
- 2015-10-30 KR KR1020150152303A patent/KR101753063B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101148513B1 (en) * | 2011-07-16 | 2012-05-21 | 최재홍 | Method for preparing producing an enrichment composition of ergothioneine from gastrodiae elata |
Non-Patent Citations (2)
| Title |
|---|
| Shizuo Toda외1명,‘Inhibitory Effects of Isoflavones in Roots of Astragalus membranaceus BUNGE(Astragali Radix)on Lipid Peroxidation by Reactive Oxygen Species',PhytotherapyResearch,12권,59-61(1998.02.01)* |
| Yu-Wei Lin 외 2명, ‘Anti-tumor activity of the fermentation broth of Cordyceps militaris cultured in the medium of Radix astragali’, Process Biochemistry 제43권제3호, 244-250쪽, 2008년(온라인공개 2007.12.15)* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210031285A (en) | 2019-09-11 | 2021-03-19 | 선문대학교 산학협력단 | Formononetin 7-O-phosphate and Composition for Anti-inflammatory Comprising the Same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170050572A (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101753063B1 (en) | The manufacturing method of the Astragalus membranaceus having increased antioxidant substances | |
| KR100988072B1 (en) | Fermented dendropanax morbifera lev. products and a pharmaceutical composition comprising the same | |
| KR100922311B1 (en) | Methods of culturing Inonotus obliquus, Phellinus linteus, Ganoderma lucidum, Sparassis crispa and Vegetable Worms for production of substances containing AHCC | |
| KR101269410B1 (en) | Methods of culturing Inonotus obliquus, Phellinus linteus, Ganoderma lucidum, Sparassis crispa and Vegetable Worms using mushroom media | |
| KR101851195B1 (en) | Fermented mulberry leaves, femented mulberry leaves extract and use there of | |
| KR101482873B1 (en) | Fermentation metabolite of Dendropanax morbiferus produced by liquid-state fermentation and manufacturaring process for the same | |
| KR101718323B1 (en) | Pharmaceutical composition containing fermented Rhus verniciflua extracts for prevention or treatment of gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric mucosal injury | |
| KR101729003B1 (en) | Composition For Preventing or Treating Gout Containing Extracts or Fermentation Metabolites of Dendropanax morbiferus | |
| KR100340663B1 (en) | A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use | |
| KR101219650B1 (en) | Process for detoxification of Rhus Verniciflua, and the use of detoxified bark extract | |
| KR101745597B1 (en) | Fermented persimmon leaves, femented persimmon leaves extract and use there of | |
| KR102507651B1 (en) | Fermented Stauntonia hexaphylla for hangover relief, alcoholic liver disease or liver function improvement using fermented enzyme complex solution containing traditional brewery yeast and its manufacturing method | |
| KR20080077524A (en) | Endo-polymer and exo-polymer obtained from submerged mycelial culture of cordyceps militaris increasing immuno-modulating activities and optimum culture conditions for producing the same | |
| KR100572405B1 (en) | Process for preparing nontoxic Rhus Verniciflua extract, and the use of the extract | |
| CN104381992A (en) | Eucommia ulmoides olive fungal substance sugar-free food and preparation method thereof | |
| KR101908727B1 (en) | Manufaturing method of morus bark having increased antioxidant substance | |
| KR101981571B1 (en) | Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating hepatic injury | |
| KR101962893B1 (en) | Composition of comprising vegetable worms extract cultured using mealworm or pupa and process of fabrication the extract | |
| KR101975018B1 (en) | Composition for lowering cholesterol comprising a mixture culture of Ginseng Berry-Auricularia auricula mycelia | |
| CN105233274A (en) | Oral composition containing cistanche and enzymes | |
| KR101994618B1 (en) | A composition for skin smoothing comprising an extract of fermented ponciri fructus | |
| KR100385658B1 (en) | A grain culture composition of inonotus obliquus, a method of preparing the antitumor and immuno-activity polysaccharide from it and their use | |
| CN105434344B (en) | A kind of anti-enterovirns type 71 oral solution of grifolan and preparation method thereof | |
| KR20050036004A (en) | Process for preparing nontoxic rhus verniciflua extract, and the use of the extract | |
| KR20180125354A (en) | The ointment treating composition containing Natural complex mushroom for improving atopic dematitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |